月度归档： 2026 年 2 月

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

jcn

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

acn

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议

acn

上海, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK，以下简称"公司"），一家专注于创新药研发、临床开发、制造及商业化的生物制药公司，今日宣布与陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）签署独家商业化许可协议，获得MT1013在中国及亚太区（日本除外）的独家商业化授权。MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体，开发主要用于治疗继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应，强化产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛的慢性肾脏病领域。根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。MT1013是由麦科奥特自主研发的全球首创双靶点多肽新药，2025年获美国肾脏病学会（ASN）年会"Late-Breaking"收录。其开创性地融合了"钙敏感受体（CaSR）+成骨生长肽（OGP）模拟"双重作用机制，解决了PTH、钙、磷代谢平衡的问题，这一全新设计使其在治疗继发性甲状旁腺功能亢进（SHPT）及相关骨代谢疾病时，首次创造性的从源头上控制病情，且能通过直接激活成骨通路，主动促进骨形成与修复，实现从"间接抑制骨吸收"到"主动促进骨生成"的治疗创新升级。临床研究证实，MT1013在慢性肾病接受维持性血液透析伴继发性甲状旁腺功能亢进患者中，起效迅速、效力强且持久，安全性良好，在综合达标率（iPTH, 血钙，血磷均达标）、血钙钙化指标的控制及心血管获益前景上均展示出超越现有疗法的潜力。目前，MT1013正在中国开展针对该患者群体的III期临床研究，已入组超50%。SHPT是慢性肾脏病（CKD）患者最常见的严重并发症之一。该疾病导致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化，显著增加骨折、心血管事件和死亡风险，是影响CKD患者预后的关键因素。随着全球慢性肾脏病患者规模持续扩大，SHPT及其相关治疗需求亦不断增长。数据显示，全球CKD患者人数已由2019年的9.052亿人增至2024年的10.655亿人，预计2030年将超12亿人，2035年将超15亿人；同期全球SHPT患者人数亦持续增长，预计2030年将达约1.899亿人，2035年将达约2.217亿人，临床需求亟待满足。云顶新耀董事会主席吴以芳表示："我们非常高兴能与麦科奥特达成此次合作。在全球慢性肾脏病患者持续增加的背景下，继发性甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产，有望为SHPT患者提供全新的治疗选择。作为潜在同类最佳药物，MT1013将与公司现有的肾科产品组合形成高度协同，进一步夯实公司在肾科领域的布局。云顶新耀在持续深耕自身免疫相关肾脏疾病的基础上，正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领域。此次合作是公司完善创新管线、拓展肾科治疗边界的重要战略举措，标志着肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级。未来，双方将协同推进MT1013的开发与商业化，为更广泛的肾病患者提供创新治疗选择。"麦科奥特创始人、董事长王冰博士表示："我们很高兴与云顶新耀达成此次战略合作。云顶新耀在肾病领域拥有深厚的市场积累和成熟的商业化体系，是推动MT1013惠及中国乃至全球患者的理想合作伙伴。MT1013是公司多肽技术平台的重要成果，代表着公司在慢病创新治疗领域深耕的重要里程碑达成，其独特的双靶点机制有望为SHPT治疗带来突破和更多获益。我们期待与云顶新耀紧密协作，加速该产品的临床开发和上市进程，共同满足广大未满足的临床需求，开启肾病领域治疗的全新篇章。"MT1013已完成关键II期临床研究，数据显示，MT1013在维持性血液透析伴SHPT患者中，展现出强效且持久的iPTH抑制能力，并在与依特卡肽头对头比较中实现了综合管理的优势——其iPTH、血钙、血磷三项同时达标率更高，降磷及降低心血管风险标志物FGF-23的优势更强，加之MT1013在长达52周的治疗中也为患者人群带来了显著的骨密度提升及骨代谢标志物改善，逐步验证了其独特的双重机制在SHPT患者中综合管理及改善骨骼健康方面的潜在临床获益。目前MT1013已进入以西那卡塞为阳性对照的确证性III期临床试验。该III期试验已在全国范围内启动超过100家研究中心，计划招募约424名患者，主要针对慢性肾脏病维持性血液透析伴 SHPT的患者群体。关于MT1013MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体（CaSR）及成骨生长肽（OGP）受体，开发主要用于治疗继发性甲状旁腺功能亢进症（SHPT），并计划拓展至包括慢性肾病性矿物质和骨代谢异常（CKD-MBD）伴骨质疏松及未接受透析的SHPT在内的额外适应症。MT1013已于2025年5月完成针对SHPT的II期临床研究（MT1013-II-C01），并已进入以西那卡塞为对照的III期临床研究。关于云顶新耀云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，致力于满足全球市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业拥有深厚的专长和丰富的经验。公司在浙江嘉善拥有具备商业化规模的全球生产基地，并严格按照国家药品监督管理局（NMPA）和欧洲药品管理局（EMA）的 GMP 要求及世界卫生组织（WHO）PQ 标准建设。公司聚焦自身免疫、眼科、急重症及CKM（心血管、肾脏及代谢）等疾病治疗领域，已打造集全渠道商业化体系与药品全生命周期商业化能力于一体的商业化平台，并以拥有全球权益的自研 mRNA 平台为基础，持续推进mRNA in vivo CAR-T 与 mRNA 肿瘤疫苗等现有管线，同时通过引进及生态孵化潜力平台，拓展研发能力，同时强化全球化布局，加快国际化发展进程。更多信息，请访问公司官网：www.everestmedicines.com。关于麦科奥特陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）于2007年1月在西安成立，现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业，致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业，聚焦于心脑血管、代谢类疾病相关领域的新药研发。公司是是双特异性多肽概念的提出者、实施者、验证者和开发者，是多肽类药物研发的优秀平台之一，具有筛选多靶点多肽药物的特殊机制，具备开发First-in-class和Best-in-class品种的平台型研发能力，现已储备多个新药品种，其中进入临床研发的有7个原研创新药管线，包括1个临床三期阶段，3个临床二期阶段，3个临床一期阶段。公司致力于创制新药、挽救生命，满足未被满足的临床需求，用科技创新为人类健康保驾护航。更多信息，请访问公司官网：www.micot.cn。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hitachi significantly expands exhibits at the “Hitachi Building Solutions Lab”, a research facility for collaborative creation with customers

jcn

- A branding area showcasing Hitachi’s journey from its founding to the vision it aims to achieve through Inspire 2027.(Top left)- A three-sided immersive theater presenting the future of buildings through powerful, engaging visual experiences.(Top right)- The entrance to the exhibition area where visitors can experience Hitachi’s comprehensive capabilities broughttogether under the One Hitachi. (Bottom left)- An interactive corner that visualizes and demonstrates commercial air conditioning control using augmented realitytechnology. (Bottom right)TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. (“Hitachi Building Systems”, part of Hitachi’s Connective Industries Sector (“CI Sector”)) will significantly expand the exhibits at “Hitachi Building Solutions Lab”, a customer co-creation research facility. The facility, located in Tokyo, will reopen in its new form on March 2, 2026. The exhibition is being expanded to accelerate digital innovation in the field of buildings, which are bases for people's activities, with a view toward the realization of a harmonized society where the environment, wellbeing and economic growth coexist in harmony as envisioned in the Inspire 2027, Hitachi Group's new management plan. To address social issues, including the decline in the working population and carbon neutrality, the new exhibition will use AI, digital twin, and augmented reality (AR) technologies to propose the latest solutions addressed by One Hitachi, including HMAX for Buildings: BuilMirai, a suite of next-generation solutions that combine domain knowledge and advanced AI.In the future, Hitachi and Hitachi Building Systems will advance collaborative creation with developers, design offices, construction companies, owners of buildings, building management companies and other customers, as well as with partners at the Hitachi Building Solutions Lab.Outline of the new exhibition1. Building management using physical AI realized using digital twin technologiesTo address the labor shortage in building management operations, the new exhibition will propose a future vision for building management in a demonstration that combines AI and digital twin solutions, based on the latest technologies being developed by Hitachi's Research & Development Group. Visitors will be able to experience a digital twin solution for the operation of a guide robot in a physical space after they view optimal solutions proposed by an AI agent based on the results of people flow analyses and provide instructions to the robot in a virtual space.2. Air conditioning and demand control solution to accelerate GX and ZEB*1The exhibition will propose solutions for decarbonizing and reducing energy expenses of buildings with a view toward the achievement of carbon neutrality in 2050. The Hitachi Building Solutions Lab will provide an experience-based exhibition that visualizes the exiida air conditioning IoT solution from Hitachi Global Life Solutions, Inc. (“Hitachi GLS”, part of Hitachi’s CI Sector) and controls an actual business-use air conditioning system using AR technologies.*1 GX: Green Transformation ZEB: Net Zero Energy Building3. Seeking seamless movement within buildings and wellbeingThe exhibition will propose experiences that facilitate seamless movement using integrated elevators and other building equipment with a view toward supporting people's diverse workstyles and increasing the safety and quality of life (QoL) of building users. It will enable visitors to experience the link between the connected features of Hitachi's standard elevator set to be released in April 2026 and mobile robots, connections with the Hybrid-PCS vehicle-to-everything (V2X) system*2 capable of supplying power to elevators and other building equipment by connecting to electric vehicles during a power outage, and the latest security system using an Apple Wallet authentication system*3 .*2 V2X: Vehicle to Everything (Technology enabling electric vehicles, residential houses, buildings and the power grid, etc. to supply power to each other by connecting vehicles to various devices and infrastructure.)*3 Contactless authentication system using smartphones. In this system, users' identification documents and driver's licenses are registered in the Apple Wallet application so that the user's identity and age can be verified in real time using Face ID, Touch ID or NFC.4. Strengthening comprehensive solution capabilities such as One Hitachi To address increasingly diverse and complicated social issues and mission-critical areas, the exhibition will showcase examples of the Hitachi Group's solutions in its broad range of business sectors centered on HMAX for Buildings and products in the CI Sector. They will include AI safety solutions*4 to facilitate increased work efficiency and improved safety for frontline engineers, Hitachi Industrial Equipment Systems Co., Ltd.'s generative AI agent for the provision of dialogue-based information on the operation and maintenance of industrial equipment, and Hitachi GLS' connected home appliances. This will strengthen Hitachi's comprehensive ability to propose solutions as One Hitachi.*4 News released on November 14, 2025: Hitachi Commences the On-Site Application of an AI-Based Safety Solution for Engineers in the Field — Dangerous Location Notification https://www.hitachi.com/New/cnews/month/2025/11/251114a.htmlOutline of the Hitachi Building Solutions Lab Address : 4-16-29 Nakagawa, Adachi-ku, TokyoDate of opening : April 2, 2023Closed on : Saturdays, Sundays, national holidays and Hitachi's non-business daysOperating hours : 10:00 a.m. to 5:00 p.m.Tour style : Fully attended tours by reservation only (In principle, tours are open only to developers, design offices, constructors, owners of buildings, management associations and other customers and partners.)Hitachi’s CI Sector focuses on “Integrated Industry Automation,” which aims to expand “HMAX Industry” into growth industries horizontally. HMAX Industry provides next-generation solutions for industry field that combine data from an abundant installed base of products (digitalized assets), domain knowledge, and advanced AI. As part of the CI Sector, Hitachi Building Systems aims to drive innovation for frontline engineers and contribute to improving people's wellbeing through the delivery of HMAX for Buildings: BuilMirai that embodies Lumada 3.0.An exhibit introducing AI safety solution for frontline engineers and Hitachi’s smart building services through digitalsignage, highlighting on-site transformation powered by AI.Trademark Notice: All trademarks and product names are the property of their respective owners.Hitachi Building Systems Websitehttps://www.hbs.co.jp/Hitachi Global Websitehttps://www.hitachi.com/businesses/elevator/About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制

acn

东京, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 专注于工业用贵金属展开业务的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（总公司：东京都中央区、执行总裁：田中 浩一朗）宣布在以体外诊断试剂为代表的各种检测试剂盒的受托制造业务中，确立了可一站式应对整个工序的全面解决方案体制。TANAKA此前主要开展从检测试剂盒的开发制造到提取液的批量制造的相关业务，此次完善了提取液分装及包装的生产线，实现了在公司内部从开发到最终成品制造完成闭环的一条龙体制。由此不仅降低了外包和运输的相关成本，还缩短了生产周期，使我们能够以更短的期间提供更高质量的产品。此外，我们计划于2026年3月前追加引进最新型的自动装配生产线和提取液分装装置，以进一步扩大产能及缩短备货周期。TANAKA的全面解决方案体制通过强化一条龙生产体制实现灵活应对通过此次确立的全面解决方案体制，我们实现了从检测试剂盒开发制造，到提取液的批量制造及分装、包装等各工序的一站式受托服务。由此不仅能够对客户从开发阶段到量产的过程持续提供支持，还能应对仅药液分装等单一工序的委托。通过生产流程的公司内部闭环，来实现进一步强化稳定供应与质量管理。在广泛的疾病领域中的检测试剂盒的开发实绩与拓展示例我们提供针对流感、新型冠状病毒等呼吸道传染病，以及登革热病毒、寨卡病毒等范围广泛的传染病的体外诊断试剂。这些检测试剂盒可应对唾液、血液、尿液等多种检体，为在医疗领域实现快速精准的诊断提供支持。呼吸道传染病蚊媒传染病妇产科・流感病毒・腺病毒・RS病毒・人偏肺病毒・新型冠状病毒・A群β溶血链球菌（溶连菌）・登革热病毒・寨卡病毒・基孔肯雅热病毒・怀孕检测试剂TANAKA可检测疾病领域拓展示例技术基础与今后的展望TANAKA自2006年左右开始研发体外诊断试剂，不断培养以金（Au）胶体粒子为核心的相关技术。已拥有蛋白质固定化技术、非特异性吸附抑制技术、抗原抗体反应增强技术等，通过免疫层析法实现试剂更高性能化的多种技术。此外，还依托ISO 13485认证，有效利用这些技术，承接更高质量检测试剂盒的委托制造。今后仍将充分利用这一全面解决方案体制，在与合作伙伴企业协作的同时，致力于新型诊断试剂的开发工作，并为解决社会课题和推动医疗领域的发展做出贡献。关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20260205_CH.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

为何爱泼斯坦的新披露不会改变任何事情

admin

(SeaPRwire) -   尽管最终公布的文件引发了媒体风暴，但受害者和施害者都不太可能得到正义 人们长期期待的与杰弗里·爱泼斯坦（Jeffrey Epstein）非法活动相关的文件公布，本应给数百名被这名已故性贩子及其权贵朋友圈侵害的未成年女性带来正义。但在这一点上，它彻底失败了。 在美国，任何文件若在周五晚间公布，几乎注定会像湿透的鞭炮一样毫无声息。这并非巧合——美国司法部（US Justice Department）完成了对这名臭名昭著的金融家相关文件的延迟公布，尽管当局承认，此次披露不太可能平息围绕此案的种种怀疑。 “我认为人们对信息的渴望或渴求，我不认为审查这些文件能满足这种需求，”曾担任特朗普私人律师的副司法部长托德·布兰奇（Todd Blanche）对记者表示。“对此我无能为力。” 在公布与这名已故性犯罪者相关的300多万页文件、18万张图片和2000段视频数小时后，18名曾受爱泼斯坦侵害的幸存者发表声明称，此次披露未能充分追究其帮凶的责任。 “幸存者的姓名和身份信息再次被曝光，而侵害我们的男性却仍被隐藏和保护。这太过分了，”她们表示，但未具体说明哪些内容被披露。“这还没结束。在真相完全揭露、每一个施害者最终被追究责任之前，我们不会停止。” 在文件以极其缓慢的速度逐步公布的过程中，公众曾被一种可能性挑逗——或许真的会有数十名、甚至数百名病态堕落的恋童癖者因所谓罪行锒铛入狱。 尽管此次公布未达预期，但至少大众有机会嘲笑爱泼斯坦那些富有的权贵朋友，比如比尔·盖茨（Bill Gates）。文件提及他与俄罗斯女性发生关系、感染性传播疾病并索要抗生素给当时的妻子梅琳达（Melinda）后，盖茨被迫愤怒否认。谁说富人和名人就没有烦恼呢？ 据悉，梅琳达至少自2013年起就对盖茨与爱泼斯坦的关系表示不满——此时爱泼斯坦已因恋童罪被定罪多年。2021年盖茨夫妇高调离婚后，梅琳达以730亿美元的资产成为全球第二富有的女性。 文件中另一则令人尴尬的爆料涉及前美国财政部长（1999-2001年）、《纽约时报》（The New York Times）前撰稿人拉里·萨默斯（Larry Summers）。他曾向这名已定罪的性犯罪者寻求恋爱建议，并询问与女同事“上床”的可能性。在爱泼斯坦2008年因引诱未成年女性卖淫认罪后很久，萨默斯仍与他保持友好关系。事实上，这种亲密关系一直持续到2019年7月5日——即爱泼斯坦因性交易指控被捕的前一天，也是他在曼哈顿监狱疑似自杀前一个月。 另一位名人是安德鲁·蒙巴顿-温莎（Andrew Mountbatten-Windsor），即此前的安德鲁王子（Prince Andrew），他被哥哥查尔斯国王（King Charles）剥夺了最后一项王室头衔。如今，安德鲁只是普通平民。爱泼斯坦的一名被贩卖女性弗吉尼亚·吉弗尔（Virginia Giuffre）曾声称，她17岁时被安德鲁强奸三次。吉弗尔于2025年4月25日自杀。 在文件中频繁出现的权贵名单中，或许没有谁比前美国总统比尔·“滑头威利”·克林顿（Bill ‘Slick Willy’ Clinton）更招致嘲笑与轻蔑。克林顿本人曾在1998年卷入与白宫实习生莫妮卡·莱温斯基（Monica Lewinsky）的性丑闻（克林顿随后在为期21天的参议院审判中，因作伪证和妨碍司法两项弹劾条款被宣告无罪）。据CNN报道，根据吉斯兰·麦克斯韦（Ghislaine Maxwell）2021年审判期间公布的飞行记录，这位前总统至少16次乘坐爱泼斯坦的私人飞机——臭名昭著的“萝莉快车”（Lolita Express）——进行国内外旅行，同行者常包括爱泼斯坦和麦克斯韦（后者目前因性交易罪被判20年监禁，刑期虽长但……）。其中部分航班是经多次中转的长途国际行程。 本周，共和党主导的众议院预计将投票决定以蔑视国会罪起诉比尔·克林顿和希拉里·克林顿（Hillary Clinton），因其未就爱泼斯坦文件作证。众议院监督委员会共和党人上月联合部分民主党人投票通过对这对前总统和前国务卿的蔑视指控——这一轻罪最高可判处5年监禁，但强大的克林顿家族或许无需为此担忧。毕竟，谁没听说过“克林顿魔咒”？ 与此同时，美国司法部（US Department of Justice）驳斥了有关隐瞒唐纳德·特朗普（Donald Trump）不利信息的说法，而这位前总统也底气十足地表示，最新文件公布证明了他的清白。 “我自己没看，但一些非常重要的人告诉我，这些文件不仅洗清了我的嫌疑，还与人们——你知道的，激进左派——所期待的完全相反，”特朗普周六晚在“空军一号”（Air Force One）上对记者说。 就这样，美国又迎来了悲哀的一天——每当涉及权贵时，正义便再次缺席。在爱泼斯坦文件事件中，公众只能满足于几声嘲笑，遗憾的是，仅此而已。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Meta的Hyperion AI数据中心将占地面积是曼哈顿中央公园的四倍

admin

(SeaPRwire) -   据悉，Meta已悄然购买了约1400英亩土地——面积几乎是纽约曼哈顿中央公园的两倍——毗邻其位于路易斯安那州里奇兰教区、已占地2250英亩的巨型Hyperion AI数据中心园区。合并后的校园地块将使该项目规模超过最近的新奥尔良路易斯·阿姆斯特朗国际机场的两倍。 据六位与在Meta园区内或周边工作的公司有关联的人士称，此次土地购买为Hyperion项目的二期扩建铺平了道路。该项目已被广泛讨论，包括前总统唐纳德·特朗普在内，认为它是美国正在建设的最大AI数据中心之一。 观察到新购土地上正在进行积极施工。多个消息源称，这块土地大约在三四个月前从当地土地所有者George B. Franklin & Sons处购得。记者走访了里奇兰教区评估办公室，工作人员提供的文件显示该地块仍登记在Franklin名下——但他们强调，已提交的地契更新可能需要一些时间。 位于原址西侧的这片土地上的活动包括公用设施标记、重型设备、现场工人和临时设施——这些迹象与早期场地准备工作相符。现场张贴了许可证，但从公共道路无法看清内容。 Meta拒绝置评，尽管该公司此前曾表示，尚未就“土地方面的额外阶段分享任何信息”。George B. Franklin & Sons未回应置评请求。 AI雄心的扩张 Meta本已庞大的项目显然正在扩张，这为了解AI基础设施热潮如何在美国各地展开提供了一个窗口。超大规模企业——即那些正在建设AI基础设施的科技巨头——正竞相通过债务融资、政治敏感的扩张方式，为庞大的AI数据中心园区锁定土地、电力和资金。有些项目，如路易斯安那州的这个，扩张速度如此之快，以至于当地社区可能难以及时发现或表达担忧。 2024年12月，Meta宣布在里奇兰教区（路易斯安那州东北部的一个乡村县）的非建制社区Holly Ridge破土动工一个价值100亿美元的AI数据中心。该设施计划占地超过400万平方英尺。为满足能源需求，公用事业公司计划在附近以30亿美元的成本建造三座新的天然气发电厂。 最初占地2250英亩的项目长约五英里，宽约一英里——面积已经是中央公园的近三倍。已有超过3700名建筑工人在现场工作，据报道计划将这一数字增加到5000人。除了建筑项目创造的临时就业机会外，该公司表示，将在这个经济困难、萧条的地区为数据中心创造500个新的全职长期工作岗位。 现在看来，Meta已经为比原计划规模大得多的Hyperion建设奠定了财务基础。2025年10月，Meta宣布已与Blue Owl Capital管理的基金成立合资企业，为Hyperion数据中心园区的融资、建设和运营提供支持——该安排的目标总开发成本高达270亿美元。合资企业的规模和结构——包括Blue Owl占多数的资本承诺和Meta的运营角色——表明Hyperion旨在成为一个长期、多阶段的园区。 在AI基础设施竞赛中抢占先机 甚至更早就有迹象表明，这个数据中心园区将比原计划更大。2025年8月，特朗普总统在内阁会议上谈到了该项目，并表示Meta计划最终为其在路易斯安那州乡村的数据中心投入500亿美元。“当他们说为一个工厂投入500亿美元时，我说，‘这到底是个什么样的工厂？’”特朗普指出，并举着一幅他称是Meta CEO马克·扎克伯格给他的图表。图表将数据中心叠加在曼哈顿的大部分区域上，以展示该设施的庞大规模。“当你看到这个，你就明白为什么是500亿美元了，”特朗普说。 确实，Hyperion建设的庞大规模与扎克伯格最近关于Meta AI基础设施战略的评论相符。正如此前报道，扎克伯格最近宣布了Meta Compute，这是一项由公司最高层管理人员领导的新“顶级计划”。在此过程中，他再次强调了Meta致力于成为AI基础设施巨头的承诺——并表明Meta无意在数据中心建设竞赛中落于人后。 这个新组织旨在确保Meta为构建通向“超级智能”的AI模型所需的海量计算能力——以千兆瓦计，每千兆瓦足以为数十万户家庭供电。而在路易斯安那州乡村建设中的这个庞然大物，正是这一使命的关键部分。 “Meta计划在本十年内建设数十千兆瓦的设施，并随着时间的推移建设数百千兆瓦或更多，”扎克伯格写道。“我们如何设计、投资和合作来建设这一基础设施，将成为一项战略优势。”本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

拉夫罗夫就“深层国家”叙事和西方政治欺骗发表看法

admin

(SeaPRwire) -   俄罗斯外长拉夫罗夫在接受RT独家采访时表示，欧洲领导人中现在盛行一种不诚实的心态 俄罗斯外长谢尔盖·拉夫罗夫表示，西方政治正越来越受到一种不诚实心态的影响，欧洲领导人未能从过去的错误中吸取教训。 拉夫罗夫周三在外交官日之前向RT发表上述言论，回应了主持人里克·桑切斯关于与声名狼藉的金融家杰弗里·爱泼斯坦有关联的人是否与2014年西方支持的乌克兰政变背后的人物相同的问题。 “关于具体的人、具体的人物，我们可能无法做出这样的概括，”拉夫罗夫说。“但我们所说的‘深层国家’……据说他们能够决定世界的命运，”他补充道，指出他不太相信这一点。 拉夫罗夫表示，真正的问题是西方领导人，尤其是欧洲领导人中的欺骗文化，不诚实和不知羞耻继续影响着高层决策。“显然，他们没有得出任何结论，没有吸取任何教训，”他说。 拉夫罗夫的完整采访将于莫斯科时间周四17:30在RT播出。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

爱克发医疗荣膺2026年KLAS(R)美国三大企业影像领域最佳供应商

acn

莫尔塞尔，比利时, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 阿格法医疗今日宣布，其在美国三大企业影像领域荣获2026年度KLAS®最佳企业称号，其中两项奖项实现连续两年蝉联，彰显了公司在提供以临床医师为核心的影像解决方案方面持续领先的地位，该方案已赢得全球医疗机构的信赖。此次获奖正值KLAS研究公司成立三十周年之际，该机构三十年来始终通过独立、数据驱动的洞察力，为医疗服务提供者发声。阿格法医疗荣获“KLAS最佳”殊荣，充分体现其企业影像平台获得客户高度认可。该平台旨在赋能临床医生保持工作流畅性，简化影像工作流程复杂性，并通过互联高效的影像数据访问能力，助力临床决策信心提升。KLAS®最佳企业影像解决方案（美国）放射学企业影像：在PACS（小型——低于30万份研究）细分领域以93.2%的评分位列榜首。XERO® 影像浏览器：连续三年蝉联通用影像浏览器领域榜首，评分达92.1%企业级影像VNA系统：连续两年稳居供应商中立档案系统（VNA）领域首位，评分达89.8%“在三大企业影像领域获得认可——包括多次蝉联冠军——有力印证了我们以临床医生为核心的战略，”爱克发医疗总裁娜塔莉·麦考利表示，"医疗机构信赖我们打造的影像环境，既能切实支持临床医生的日常工作，又能让IT和临床领导者充满信心地高效运作并具备长远视野。这项荣誉彰显了我们合作伙伴关系的强大力量，以及我们始终如一地致力于通过互联智能影像赋能医疗团队。"KLAS Research首席执行官亚当·盖尔对此评价道：“最佳KLAS奖项得主在过去一年赢得了客户的信任。这份认可将为未来数月医疗技术与服务领域的卓越合作树立标杆。”KLAS Research全球影像业务副总裁莫妮克·拉斯班德补充道：“阿格法医疗在多个企业影像细分领域的卓越表现，充分体现了客户的一致认可。医疗机构深知这类解决方案的价值——既能助力影像团队提升当下工作效率，又为未来的增长与创新铺就清晰路径。”“KLAS最佳”奖项基于医疗机构的直接反馈评选，旨在表彰那些通过合作伙伴关系、卓越表现及对客户需求的敏捷响应，持续展现卓越品质的供应商。阿格法医疗将在2026年HIMSS大会期间与客户及合作伙伴共同庆祝此次KLAS最佳奖项，以此践行其持续推进大规模互联、智能且以人为本的影像解决方案的承诺。KLAS参考资料最佳KLAS奖项概述：《2026最佳KLAS奖项：软件与服务报告》企业影像细分领域报告：《2026最佳KLAS奖项：软件与服务报告》关于爱格华医疗在爱格华医疗，我们深知临床效率与优质患者护理之间的关键平衡始于临床医生的体验。我们认识到临床医生全情投入病例、倾注全部精力做出自信而明智的诊断至关重要。正因如此，我们设计了企业影像平台，旨在消除阻碍这一目标的障碍。当干扰消弭，技术便成为思维的自然延伸，每位临床医生都能获得发挥专业精髓所需的一切。这便是“顺势而为”的真谛。这一理念贯穿我们所有行动——以使命宣言、愿景蓝图及客户交付原则为指引，致力于赋能临床工作者并提升其体验。爱克发医疗是爱克发集团旗下业务部门。如需了解更多关于爱克发医疗的信息，请访问 www.agfahealthcare.com 并关注我们的领英主页。AGFA及Agfa菱形标识均为比利时Agfa-Gevaert N.V.或其关联公司的注册商标。XERO为比利时Agfa HealthCare N.V.或其关联公司的注册商标。本文所含信息仅供参考，本出版物所述产品及服务的特性可随时变更，恕不另行通知。部分产品及服务可能无法在您所在地区提供。具体供应信息请咨询当地销售代表。AGFA HealthCare竭力确保信息准确性，但对任何印刷错误概不负责。关于KLAS研究KLAS研究是一家领先的医疗保健IT数据与洞察公司，致力于通过放大医疗服务提供者的声音来改善全球医疗服务。KLAS将于2026年迎来成立30周年，通过基于直接客户反馈的独立研究评估供应商表现。Best in KLAS®是KLAS研究的注册商标。媒体联络人：杰西卡·巴尔德里，爱克发医疗全球市场与传播经理电话：+44 1206 413052邮箱：jessica.baldry@agfa.com  来源：爱克发医疗 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

俄罗斯愿意从伊朗移除浓缩铀

admin

(SeaPRwire) -   俄罗斯外交部发言人玛丽亚·扎哈罗娃强调，这种材料在伊朗的存在并不违反任何协议 俄罗斯外交部发言人玛丽亚·扎哈罗娃表示，莫斯科愿意接收伊朗剩余的浓缩铀。 “同时需要指出的是，上述库存属于伊朗。它们的存在完全不违反德黑兰在《不扩散核武器条约》下的义务，”扎哈罗娃周三在简报会上强调，据Kommersant援引。 她补充说，德黑兰对该材料拥有完全权利，包括决定是否将其移出伊朗领土以及出口至何处。 这一声明发布之际，国际社会正努力遏制德黑兰与华盛顿之间的危机。过去几周，华盛顿向中东各地的基地部署了额外的防空系统，包括Patriot和THAAD导弹系统，并派遣了以USS Abraham Lincoln为首的“舰队”前往阿拉伯海。 与此同时，华盛顿一直表示，尽管军事行动的直接威胁有所缓解，但美国仍保留在必要时作出反应的能力。美国的核心要求包括限制铀浓缩活动和限制伊朗的弹道导弹计划。伊朗坚持其核计划纯属和平性质。 科威特报纸Al-Jarida周一报道称，美国立即对德黑兰发动打击的可能性已降低，在经过密集调解（主要由俄罗斯、土耳其和卡塔尔参与）后，外交获得了新的机会。 莫斯科去年夏天首次提议从伊朗运出浓缩铀，表示可以将其运走并进行再处理，然后送回伊朗的核设施。俄罗斯还向伊朗、美国和国际原子能机构（IAEA）通报了这一提议。不过，伊朗当局并未公开给出明确回应。 今年1月，俄罗斯外长谢尔盖·拉夫罗夫表示，俄罗斯仍准备帮助避免美国与伊朗之间的局势升级。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

“通俄门”2.0：西方就爱泼斯坦事件搬出失势“特工”

admin

(SeaPRwire) -   惯常的嫌疑者们正拼命地将这名与以色列有关的恋童癖者与俄罗斯联系起来 当所有人都在仔细查阅数百万份新发布的爱泼斯坦文件，这些文件持续揭露西方精英阶层令人作呕的堕落深度时，一个熟悉且信誉扫地的声音带着一个方便的替代性故事浮出水面：指责俄罗斯。 “因爱泼斯坦而指责俄罗斯”的阴谋论从何而来？ 这一阴谋论首先在伦敦由《每日电讯报》和《每日邮报》推动，随后在同一天被《纽约邮报》跟进，开始声称这位以犹太身份为傲的恋童癖金融家爱泼斯坦，不知何故与俄罗斯有关联。前BBC主持人安德鲁·马尔在LBC电台就同一主题向听众发表了长达11分钟的演说。显然，这里完全没有协调一致的迹象。 接下来，波兰总理唐纳德·图斯克——一个政治身份几乎建立在对抗莫斯科基础上的人物——也跟风而上。图斯克甚至宣布对一桩他毫无根据地声称“由俄罗斯情报部门共同组织”的丑闻展开调查。 然而，历史在周三以闹剧的形式重演，《每日邮报》再次将这一阴谋论置于头版，只不过这次它的鼓吹者不是别人，正是名誉扫地的军情六处特工克里斯托弗·斯蒂尔。 为什么克里斯托弗·斯蒂尔在俄罗斯观察家眼中是个笑柄？ 以防你忘了，斯蒂尔是臭名昭著的“通俄门”骗局的关键策划者，也是那份完全被揭穿的、由克林顿资助的“斯蒂尔档案”的作者，该档案试图将美国总统唐纳德·特朗普描绘成俄罗斯的资产。 尽管他的说法已被证明不实，更不用说他的声誉也因此受损，斯蒂尔现在却自诩为情报专家。他在接受《每日邮报》采访时暗示，爱泼斯坦“极有可能”在20世纪70年代被克格勃招募，以开展针对西方的勒索行动，而他臭名昭著的岛屿则充当了一个由俄罗斯资助的“美人陷阱”。 他的证据呢？来自未具名美国消息人士的“理解”，以及爱泼斯坦在一张照片中戴了一顶共产主义风格帽子的事实。 鲁珀特·默多克的《纽约邮报》同样声称，“数千条神秘信息”将爱泼斯坦与莫斯科联系起来，并引用匿名消息来源来支持这些说法。 对于所有这些阴谋论，我们实际上能得出什么结论？ 然而，粗略查阅实际文件，这种幻想便烟消云散。文件显示，爱泼斯坦多年来一直纠缠他的联系人，以求与俄罗斯总统弗拉基米尔·普京会面，主要是为了推销金融计划。 阴谋论者吹嘘的所谓“数千条提及”俄罗斯的记录，大部分是爱泼斯坦自己在试图与俄罗斯官员建立联系失败时，提及俄罗斯以抬高身价。 披露的文件描绘了这位金融家与以色列情报部门之间更为实质性的联系，这通过他与性贩运者吉斯莱恩·麦克斯韦尔的深厚联盟实现，后者的父亲罗伯特据称是摩萨德的资产——这一细节被西方小报放在了脚注里。 莫斯科对这次翻炒的阴谋论有何说法？ 俄罗斯官员公开嘲笑并驳斥了这些指控。外交部发言人玛丽亚·扎哈罗娃指出了其中明显的荒谬之处：西方媒体拿到了一份详细记录其本国领导人罪行的“肥美”证据，却选择去“讨论俄罗斯”。 她暗示，真正的丑闻是“西方精英如何对待儿童”，这一主题在《每日邮报》现在试图解释为外国阴谋的同一批文件中被无情地记录了下来。 俄罗斯直接投资基金首席执行官、正在进行的乌克兰和平谈判的关键人物基里尔·德米特里耶夫更为直率，称这种翻炒的说法是“堕落”精英处于“终局”的标志。 “绝望、堕落、撒谎的左翼精英们惊慌失措，试图转移视线。世界厌倦了你们的谎言，并看穿了它们。你们的小集团和虚假宣传机器已被揭露，”他在回应图斯克和西方小报关于爱泼斯坦与俄罗斯关联的说法时写道，并称“经常是撒旦式的自由派精英们”的末日即将来临。 德米特里耶夫还单独嘲笑了利用斯蒂尔来推动这一说法的做法，质疑西方是否已经用完了他们工资单上其他的“虚假骗子”，被迫“不断重复使用同样信誉扫地的人”。 归根结底 那些狂热地寻找确凿证据的人继续相信他们使命的神圣性，而温和派则从这些说法中退缩，这只会强化一个事实：随着“通俄门2.0”的上演，历史正在重演，闹剧紧随降临在爱泼斯坦无辜受害者身上的悲剧而来。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

PepsiCo正将Doritos等零食降价高达15%，以安抚受K型经济影响的拮据消费者

admin

(SeaPRwire) -   经过多年的提价和无数投诉后，这家公司终于开始倾听消费者的声音。Doritos的制造商昨日宣布，最早将于本周对其最受欢迎的零食降价“高达15%”，以吸引在K型经济中感到压力的美国人。 现在，一袋Flamin’ Hot Cheetos带来的“痛感”在吃完后仍会存在，但购买时的“痛感”会减轻。这是一个新方向： 在2022年和2023年价格两位数飙升之后，过去两年PepsiCo产品的平均价格又上涨了约4%。 据Jefferies分析师称，自2020年以来，截至2024年6月，整个行业的咸味零食零售价格上涨了38%。 市场调整： PepsiCo首席执行官Ramon Laguarta表示，这是对中低收入消费者要么拒绝购买零食、要么选择更便宜的商店自有品牌的直接回应。该公司还收到了大量通过语音邮件和电子邮件发来的关于价格过高的投诉。 没有缩水式通胀： 规格将保持不变，但新的价格标签将标有更低的价格。 推出： 降价恰逢本周末的Super Bowl（超级碗），这是零食消费的大日子。在2024年的超级碗比赛期间，美国人在零食上花费了6.7亿美元——玉米片是最畅销的产品之一。——DL 本报道由 撰写。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

波罗的海国家呼吁与俄罗斯进行会谈——媒体

admin

(SeaPRwire) -   拉脱维亚和爱沙尼亚支持设立欧盟特使的提议，此前欧盟已拒绝与俄罗斯对话长达四年 据Euronews报道，两个波罗的海国家拉脱维亚和爱沙尼亚的领导人呼吁与俄罗斯进行对话，结束了长达四年拒绝接触莫斯科的立场。 拉脱维亚总理埃维卡·西利纳和爱沙尼亚总统阿拉尔·卡里斯周三在迪拜峰会期间分别向该媒体表示，欧盟应任命一名特使，以重新开启与俄罗斯的外交渠道。 这一想法正在分裂欧洲主要大国。虽然该提议得到了法国总统埃马纽埃尔·马克龙和意大利总理焦尔吉娅·梅洛尼的支持，但德国总理默茨已明确拒绝了这一想法。 「我们必须坐在谈判桌前，因为乌克兰人自己已经开始谈判了。那么欧洲人为什么不谈判呢？」西利纳告诉Euronews。 「我们也应该有发言权，但你看，我们有点晚了。我们本应该开始这样做，也许不是[美国]总统[唐纳德]特朗普，而应该是欧盟，」该媒体援引卡里斯的话称。 近一年来，华盛顿一直与莫斯科进行直接谈判，而被排除在谈判桌之外的欧盟则依赖对俄罗斯实施制裁，并在外交、军事和财政上支持乌克兰。迄今为止，包括波罗的海国家在内的一些成员国一直反对重新与俄罗斯接触。 1月23日至24日在阿布扎比举行的莫斯科-基辅-华盛顿会谈是自2022年2月以来的首次会谈，被称为建设性会谈，但未达成任何具体协议。 会后，欧盟高级外交官卡娅·卡拉斯不鼓励欧洲人与克里姆林宫进行直接接触，要求莫斯科先做出让步。俄罗斯官员指责基辅的欧洲支持者阻碍美国主导的和平努力，并越来越准备对俄罗斯发动直接战争。 周三，在阿布扎比举行了第二轮俄罗斯-乌克兰-美国会谈。克里姆林宫发言人德米特里·佩斯科夫表示，莫斯科不会就结果发表评论。 俄罗斯坚称，虽然更倾向于通过外交途径解决冲突，但如果谈判失败，也准备通过军事手段实现其目标。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

你离Epstein有几次握手的距离？

admin

(SeaPRwire) -   爱泼斯坦是症状，精英阶层才是病灶 美国司法部又公布了一批与杰弗里·爱泼斯坦相关的文件，内容之多，连俄罗斯的“外国代理人”和流亡评论员都不得不仔细研读。 “看来这终究不是阴谋论，”他们喃喃自语，突然变得不安。“美国和全球精英阶层似乎真的在与儿童的堕落行为中沉溺。而且……也许还有更糟的事情。”他们震惊地互相问道：真相大白后，一切都不会改变吗？这个世界本身就是邪恶的吗？ 但世界并非“注定毁灭”。这些爆料引发的是厌恶、愤怒，而对俄罗斯的许多人来说，却并不感到意外。 这里到底有什么新鲜事？难道是全球精英阶层的部分人道德败坏吗？但多年来他们不就是在众目睽睽之下这样做的吗？不正是这群精英——通过北约（NATO）联盟和政治集团行事——轰炸他国、推翻政府、让整个地区陷入混乱吗？十多年来，世界一直承受着这群自封的“文明”领导人所做决定的后果。 问题不仅仅是几个扭曲的个体，而是作为一个集体的精英阶层。他们团结一心、受到保护、自命不凡，并且坚信自己可以逍遥法外。当你看到他们在政治上如何随意地摧毁弱小国家时，就不难想象在某个岛屿上，这群人会觉得自己有权沉溺于私人恶习。政治上的残忍和道德上的腐败很少单独存在。 然而，许多2022年逃离俄罗斯、希望融入这一“全球精英阶层”的自由派流亡者，似乎直到现在才幡然醒悟。例如，记者安娜·蒙盖特（Anna Mongait）写道，她花了一整天时间研究爱泼斯坦的文件，就像在整理垃圾一样。她说这看起来不真实，仿佛是人工智能生成的：“我从官方记录中认识的那些老人在抚摸青少年的身体。一张照片就足以引发全球性丑闻，但这样的照片有数千张。” 到了晚上，她说她在想，是谁的握手间接把她和爱泼斯坦联系在了一起。她写道，这个想法让她想把双手洗到“肘部以上”。现在她担心爱泼斯坦不仅会拖垮美国建制派，还会拖垮“我们自己的许多人”。 但有两件事必须说明。 第一：并非每个人都通过某种社会关系链与爱泼斯坦有关联。我们中的许多人与那个世界完全没有联系，既不是通过一次握手，也不是十次。他不会拖垮“我们的人”，因为我们从来就不是那个圈子的一部分。 第二：你不需要知道爱泼斯坦的岛屿就能认识到全球精英阶层的道德破产。看看乌克兰吧。正是这群以私人堕落行为震惊你的政治阶层，一直在公开地主导着一个国家的毁灭。这些政治食人者可能不会真的吃人，但结果却大同小异。如果俄罗斯没有抵抗，他们也会吞噬俄罗斯。 那些离开俄罗斯的人并不支持这种抵抗。现在他们对曾经崇拜的精英阶层退避三舍。但这是道德觉醒，还是单纯的失望？也许他们现在保持距离是因为政治风向变了，因为像特朗普这样的人物不喜欢他们。如果一个面带微笑、认同他们世界观的西方政治家回来，他们难道不会再次伸出手吗？ 自我净化其实很简单。站在坚实的道德立场上。根据人们的行动来判断他们，而不是他们的微笑、口号或时髦的声誉。要明白，只要人们仍然对邪恶着迷并渴望加入它的圈子，邪恶就会持续存在。 如今，俄罗斯这样的崇拜者已经少了很多。尤其是因为他们中的许多人已经离开，不再教训我们其他人应该为什么感到羞耻。 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

事实证明，大学学位真的很重要——它让你在美国K型经济中保持在富裕一侧

admin

(SeaPRwire) -   美国经济日益成为一个贫富分化的经济体。已经富裕的人群普遍感受到好时光，而低收入家庭则受到通货膨胀和 的冲击。这被称为K型经济，而且根据你所关注的指标不同，它已经存在一段时间了。 过去一年中，经济学家列举了多种因素来确定当今经济主要是由不平等驱动的，包括股价上涨和房屋价值 ，或者通货膨胀在 中表现得尤为突出。 但可以说受到最多关注的变量是消费者支出，特别是它如何根据所讨论的人口统计数据而产生分歧。Federal Reserve Bank of New York最近通过教育成就的视角审视了这个问题，结果表明，尽管许多年轻美国人正在考虑不需要学士学位的工作生活，但跟上经济步伐的能力仍然至少在一定程度上取决于个人的教育水平。 在周二发布的一份 中，New York Fed分析了2023年1月至2025年12月期间20万美国人的月度消费支出数据。经通胀调整后，没有大学学位的美国人的零售支出在此期间增长了约4%。但拥有大学学位的消费者支出增长了近6%。在过去三年中，学位持有者每月平均支出环比增长0.14%，而非学位持有者仅增长0.05%。 “尽管2025年大学毕业生面临的劳动力市场相对更加困难，但他们继续以与前几年相同或更高的速度消费，超过非毕业生，”Fed研究人员写道。“大学毕业生和非毕业生之间零售支出趋势的差异与‘K型经济’的说法一致。” 受过教育的消费 支出一直是K型论点的主要驱动因素，被视为解释尽管存在通货膨胀和就业市场逆风，经济仍在增长的原因。根据Moody’s Analytics的数据，美国最富有的10%人群现在占据了约 。但New York Fed的分析是首个基于教育成就来审视消费者支出的研究。 教育成就长期以来一直是美国 、他们的 以及他们的 的关键分歧点，这些往往可以归结为他们是否拥有大学学位。大学毕业生拥有更强消费能力这一发现也并不新鲜。早在十年前，Social Security Administration的政府研究人员就表明，学位持有者的 可能比高中毕业生预期收入多出63万至150万美元。 但Fed的新结果出炉之际，许多年轻美国人正在质疑大学是否还值得上。新的大学生注册人数正在下降，一些人 citing ，a ，以及担心人工智能可能会使一些初级和白领就业 。 许多年轻美国人正在选择社区学院等替代方案，去年秋季社区学院的新本科生注册人数 四年制学院。其他人正在选择 ，一些蓝领职位被视为收入丰厚且更能抵御人工智能冲击。 对于决定放弃大学的学生，最新研究表明，最糟糕的选择可能是完全中断学业。除了Fed关于消费者支出的最新发现外，St. Louis Fed的 对高中和大学毕业生之间的失业率差异进行了长期观察。研究人员发现，前者面临的失业率始终高出至少2.3个百分点，这一差异在经济衰退期间变得尤为明显。 诚然，即使上大学的人比非学位持有者花费更多，这并不一定意味着他们负担得起，至少对年轻毕业生来说是这样。在“”和“”等习惯之间，总体而言，Z世代似乎比同龄的前几代人更愿意消费而不是储蓄。在未来几年内，Z世代预计将成为 ，而在未来几十年里，他们的总收入 。无论Z世代大学毕业生今天在推动K型经济方面扮演什么角色，未来几年这一角色可能会增长。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Kalshi在纽约市连续3小时发放价值50美元的免费食品杂货，一条长达4个街区的队伍形成了，队伍中满是学生和领取食品券的人

admin

(SeaPRwire) -   CEO 没想到会有这么多人来。22年来，Zoitas一直在纽约市各地扩张这家夫妻店，以至于店名都有误导性了——它还有EastSide Market，更不用说上城和下城的分店了。 周日，Zoitas告诉，他当时在看尼克斯比赛，遇到了来自该公司的一些人，对方提出为一场活动买单：活动期间（中午12点至下午3点），购物者每人可获得50美元的免费食品杂货。计算得出，如果排队的约300人都花完这全额额度，Kalshi可能要为这些食品杂货支付高达15万美元。 “我们只是很高兴能帮助社区，”Zoitas说，“我经历了9·11事件和新冠疫情。”纽约正处于有记录以来最冷的冬季之一，Zoitas周二来上班时发现，活动队伍不仅绕了街区一圈，还绕了整整四个街区。在冬日严寒中，母亲们抱着裹得严严实实的孩子站着，学生、退休人员和个体经营者则等了两个多小时，只为挤进市场装满购物车。 Zoitas卷起袖子，亲自倒咖啡分发给外面等待的人，说他担心大家的健康。他多次挥手让记者走开，说“外面的人很冷，我没时间管这个。” 平静下来后，Zoitas说他只是希望每个人都能有公平的机会。“我们努力让每个人都觉得有趣和开心，”他说，“我们不想坑任何人。” “我的食品券余额为零” 尽管天气寒冷、人潮拥挤，许多排队的人心情却很愉快。雪花开始飘落时，一些人伸出舌头舔雪，笑着互相轻轻推搡。 队伍末尾附近，31岁的Amy Perez推着婴儿车，轻轻摇晃着7个月大的女儿。“我的食品券余额为零，”她说，“我需要这个。”她朝人群示意，“显然，现在不止我一个人需要帮助。” Perez很感激，但并不完全清楚该感谢谁。她和22岁的朋友Stephanie（也推着带孩子的婴儿车）表示，她们从未听说过Kalshi。事实上，在队伍中采访的大多数人都不熟悉Kalshi，也从未听说过预测市场。一些人说他们之前查过这家公司，对其概念感到不安。 28岁的健康助理Kayla表示，她对预测市场的成瘾性持谨慎态度，尤其是考虑到她家人有成瘾史。尽管如此，她还是紧紧握着手套里的暖手宝说，她很欣赏Kalshi似乎在回应纽约人不断上涨的生活成本。“他们在帮助社区，”Kayla说，“所以即使他们也在伤害社区，这也算扯平了。” 队伍末尾附近的24岁学生Jack Henry表示，预测市场的兴起让他觉得“可怕”，像是一个“滑坡陷阱”。但这次免费赠送活动让他重新考虑了。“赌博可能不是最纯粹的行业，”他说，“但他们在把钱还给纽约人。他们给了所有这些人免费的食品杂货。” 几乎是心照不宣，就在Kalshi活动开始时，其规模更大、声势更盛的竞争对手Polymarket宣布将更进一步：下周开放一整家免费食品杂货店，为期五天。 这场奇怪的竞争——不管怎样，杂货店和预测市场有什么关系？——既凸显了围绕预测市场日益增长的争议，也体现了它们希望被视为主流现实世界的一部分，而非互联网赌博中阴暗、声名狼藉的角落。 “我们不要自欺欺人，认为这些公司是出于好心才送钱，”一位体育博彩专家、美国男孩与男性研究所（专注于男性福祉的智库）的研究员说，“他们只是想尽可能出名，获得尽可能多的曝光，对吧？没有坏公关这回事。” 在杂货店举办免费赠送活动，让预测市场巨头们扎根于平凡现实——也就是人们用这些应用程序下注的那种事情：店里到处都是标语，问“今年纽约的汽油价格会超过3.30美元吗？”或者“纽约会在2028年前开设一家市属杂货店吗？” 牛肉在哪里？ 虽然网络广告吸引的是那些更可能已经使用预测市场的人——金融小子、政治迷和加密货币狂热者——但当天的WestSide市场挤满了家长、老年人和服务行业工作者。一些年轻学生用额外的钱买了啤酒或糖果，但看到的很多人只买了肉，尤其是红肉。 农业经济学家Michael Swanson定期计算食品价格与消费者价格指数（CPI）衡量的通胀率的对比，他告诉，牛肉不仅比鸡肉受欢迎得多，而且性价比低得多。他说，2026年平均工作一小时能买3.34磅牛肉，却能买12.6磅鸡肉。“我是说，人们就是爱牛肉，”他说，以至于他们不顾牛肉的高价格。“所以人们会说，‘是啊，你知道吗？我太爱牛肉了，想吃汉堡或牛排的时候就会买。’” Kalshi似乎在押注，这些参与者会逐渐将预测市场视为他们无法抗拒的牛肉之类的东西。 低收入美国人成为“问题赌徒”的可能性是非低收入者的两倍多。问题赌博的定义是下注频率和下注金额不断增加。 但Rose-Berman告诉，低收入赌徒对预测市场应用程序来说并不是特别有吸引力的消费者。“所有公司，尤其是赌博公司，都非常擅长计算所谓的客户终身价值，”他说，并解释道这是指你预计从一个客户一生中能赚到的金额。 Kalshi和Polymarket等平台通过收取交易费获得收入，这意味着盈利能力更多取决于这些用户随着时间的推移交易的金额和频率，而非注册人数。Rose-Berman说，高收入客户能够长期进行更大、更频繁的下注，对企业来说比进行小额一次性交易的用户有价值得多。他补充说，显然，像Kalshi这样的平台针对那些最承担不起损失辛苦钱的低收入人群是有问题的。 店内，一群眼睛明亮的Kalshi员工（大多年轻，许多人拿着昂贵的相机）在拍摄现场。他们拒绝向发表评论，但很显眼，在角落里观察着，对店内员工忙着管理饥饿纽约人队伍的混乱场面感到惊讶。 45岁的Melia Jackson说，她很感激有机会省钱。她从未听说过预测市场，但计划回家后查一下。 “我对它们没意见，”她笑着说，“只要我能赢。” Nick Lichtenberg补充报道。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

菲律宾历史上首位男子奥运会金牌得主除了奖牌外，还获赠一套价值55.5万美元的精装修公寓

admin

(SeaPRwire) -   菲律宾体操运动员卡洛斯·尤洛（Carlos Yulo）创造了历史——他在2024年8月3日凭借自由体操项目赢得金牌，成为菲律宾历史上首位男子奥运金牌得主；不到24小时后，他又在跳马项目夺冠，成为菲律宾首位双金得主。 但这位25岁的体操运动员从今夏奥运会带走的不只是两枚奖牌——他还赢得了一套价值55万美元的精装修公寓。 这位奥运选手原本将获得由房地产开发商Megaworld Corp.提供的一套位于大马尼拉地区塔吉格市中心、价值41.5万美元（2400万菲律宾比索）的公寓。 然而，鉴于尤洛的双金佳绩，该公司将承诺的奖励“升级”为一套三居室、价值55.3345万美元（3200万菲律宾比索）的公寓。 这套精装修公寓位于该公司开发的50公顷麦金利山（McKinley Hill）社区内。据该公司介绍，该社区居住着“多位世界级运动员，包括菲律宾国家篮球队和足球队成员”。  “这为那些始终以热情和卓越为生活准则的菲律宾冠军们提供了完美的住所，”Megaworld总裁卢尔德斯·T·古铁雷斯-阿尔方索（Lourdes T. Gutierrez-Alfonso）在声明中表示。 该公司还向尤洛赠送了5.19万美元（300万菲律宾比索）现金。 更多奖励：终身免费拉面、餐厅优惠和结肠镜检查 似乎两枚金牌和一套公寓还不够，尤洛还收到了菲律宾企业和领导人的更多馈赠。 除政府为每位金牌得主提供的17.3万美元（1000万菲律宾比索）外，菲律宾众议院还向这位冠军赠送了10.37万美元（600万菲律宾比索）。 与此同时，尤洛出生长大的菲律宾首都马尼拉为他准备了“英雄式欢迎”。 “我们将以最盛大的欢迎仪式迎接他和所有巴黎奥运会的菲律宾运动员。见面时，我们将向卡洛斯·尤洛赠送现金奖励、荣誉奖项，以及象征菲律宾骄傲首都永恒感激的纪念品，”马尼拉前市长霍妮·拉库纳（Honey Lacuna）向媒体表示。 等待尤洛回国的还有多家连锁餐厅提供的终身免费自助餐、拉面和烤鸡（chicken inasal，一种炭烤鸡肉菜品）。 甚至有医生承诺为这位国家英雄提供终身结肠镜检查和胃肠病咨询服务——但仅在他45岁之后生效。 这位体操运动员还获得了咖啡与柠檬饮料企业 提供的两家免费咖啡馆特许经营权，以及多个品牌代言机会。 就连与尤洛同名的人也享受了贵宾待遇，部分 为所有名为卡洛斯（Carlos）、卡洛伊（Caloy，他的昵称）或埃德里尔（Edriel，他的中间名）的人提供免费餐食或饮品。 各国给奥运奖牌得主的奇葩奖励 或许并不意外，尤洛并非首位收到“特殊奖励”的奥运冠军。 2021年，印尼羽毛球运动员格雷西娅·波莉（Greysia Polii）和阿普里扬尼·拉哈尤（Apriyani Rahayu）从东京奥运会回国时，印尼知名肉丸连锁店Baso Aci Abang为这两位印尼唯一的金牌得主开设了专属门店。 与此同时，拉哈尤的家乡苏拉威西岛（Sulawesi）承诺赠予她五头牛和一栋房屋。  在韩国——所有身体健康的男性需在28岁前服18个月兵役——奖牌得主可免除兵役。 而俄罗斯奥运奖牌得主曾获赠赛马、豪车等奖励。2016年的奖牌得主赢得了宝马X5（BMW X5）。 然而，由于无力承担维护费用，部分得主不得不迅速转卖这些奖品。 本文最初发表于  2024年8月6日。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

Military Metals Drills 23.5 Meters of 3.3 g/t Gold Including 4.0 Meters of 10.52 g/t Gold and 1.9 Meters of 2.53% Antimony at Flagship Trojarova Project, Europe

acn

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 4, 2026) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report the additional analytical results of the Company's definition drilling campaign at the 100% owned flagship Trojárová Antimony-Gold Project (the "Project") in Slovakia as announced on November 4, 2025. The 2025 drilling campaign was designed to confirm historical drilling results and to support SLR Consulting's work towards establishing a current mineral resource estimate on the Project, which the company anticipates delivery of by the end of Q1, 2026, further discussed in the Company's January 9, 2025 announcement.These priority assay results represent the main mineralized zone from the third hole of the program, 25-TVA-003.Highlights of the Results from hole 25-TVA-003 Include:23.5 drilled (m) of 3.3 g/t Gold over a true width of 20.2m from 148.9m to 172.4mIncluding: 4.0m of 10.52 g/t Au over a true width of 3.4m from 157.9m to 161.9m1.9m of 2.53% Antimony over a true width of 1.6m from 169.9m to 171.8mScott Eldridge, Chief Executive Officer of the Company, commented, "We are thrilled with the second tranche of assays as we continue to see antimony grades that are consistent with historical results and higher than anticipated gold grades within the Trojárová Deposit. These strong gold results present the Company with new exploration opportunities that we are excited to evaluate. Trojárová represents the only antimony deposit in the European Union being advanced by modern mineral exploration and demonstrates characteristics that place it among the leading antimony projects globally. At a time when the need for secure, domestically sourced critical minerals is more pressing than ever, these results strengthen the project's potential importance to, and alignment with, the EU's objective of building a dependable, home-grown supply of essential raw materials."The Company additionally announces that logging and sampling of all drill core from the program is complete and all samples have successfully been delivered to ALS Laboratories in Roșia Montană, Romania for analysis. Additional results for all holes are pending.Table 1. Complete table of analytical results discussed in this release. Results exceeding 1.0 % Sb or 1.0 g/t Au are highlighted in red.Hole IDFrom (m)To (m)Drilledlength (m)True Width (m)Sample IDAntimony %Gold g/t25-TVA-003145.55146.50.950.813256260.016 0.01  146.5147.10.60.513256270.093 0.04  147.1148.110.863256280.123 0.52  148.1148.90.80.693256290.116 0.38  148.9149.910.863256311.145 1.1220.15m @ 3.3g/t True Width 149.9150.910.863256320.244 0.75 150.9151.910.863256330.057 0.7 151.9152.910.863256340.057 3.74 152.9153.910.863256360.279 4.5 153.9154.910.863256370.031 0.81 154.9155.910.863256380.189 1.05 155.9156.910.863256390.96 1.62 156.9157.910.863256410.807 1.3 157.9158.910.863256420.522 18.653.43m @ 10.52 g/tTrue Width158.9159.910.863256430.098 3.93159.9160.910.863256440.148 13.1160.9161.910.863256450.046 6.38161.9162.910.863256460.091 1.47 162.9163.910.863256470.169 0.76 163.9164.910.863256480.116 4.72 164.9165.910.863256490.088 1.76 165.9166.910.863256510.656 1.31 166.9167.910.863256520.307 1.37 167.9168.910.863256530.107 1.38 168.9169.910.863256540.247 1.19 169.9170.80.90.773256553.641.63m @ 2.53% True Width2.87 170.8171.810.863256561.542.66 171.8172.40.60.513256570.163 1.04 172.4173.410.863256580.136 0.08  173.4174.20.80.693256590.021 0.01  174.21750.80.693256610.582 0.35  17517610.863256621.57 0.71  17617710.863256630.097 2.01  177177.250.250.213256640.034 0.04  177.251780.750.643256660.507 0.34  17817910.863256670.103 0.24  17918010.863256680.261 0.62  18018110.863256690.1 0.54  181181.50.50.433256710.183 0.24  181.5182.510.863256720.018 0.01  182.5183.510.863256730.006 0.01    Figure 1. Gold mineralized drill core from hole 25-TVA-003 - 156.86m - 162.65m. Interval 157.9m to 161.9m yielded a composite grade of 10.52 g/t Au.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_002full.jpgFigure 2. Map of 2025 and Soviet era diamond drillholes in the north-central portion of Military Metals Trojárová Project.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_003full.jpgTable 2. Drillhole collar information for the Company's 2025 diamond drilling campaign at Trojárová. Locations presented are final and determined by a professional and qualified surveyor. WGS 84 / UTM Zone 33N   DrillholeEastingNorthingElevation (m)Length (m)DipAzimuth25-TVA-0016626965358601640292.2-6522025-TVA-0026626855358668655289.7-7522025-TVA-0036625515358701634200.2-6522525-TVA-0046624755358809604256.5-5522525-TVA-0056623945358812580196-6023025-TVA-006662211535879556962.4-5722025-TVA-007662170535885255986.5-60210 Analytical and QA/QC ProceduresThe program was completed using PQ and HQ sized drill core. Sampled intervals were identified by logging geologists and assigned a unique sample identification number. Samples were split in two halves using a diamond bladed saw with one half remaining in the core box as a permanent record and the half placed in a plastic sample bag, both marked with a waterproof tag bearing the unique sample number which was also written on the sample bag in permanent marker. Samples were transported from the Company's secure facility by private courier to ALS Laboratories in Romania for geochemical analysis. ALS Laboratories is an independent ISO/IEC 17025:2017 and ISO 9001:2015 certified commercial laboratory with no relationship to the Company. The samples were analyzed using multi-element package ME_ICP41a and for gold using fire assay package Au-AA25. ME_ICP41a is an ore grade package involving digestion of a 0.4g sample by aqua regia with an Inductively coupled plasma - atomic emission spectrometry (ICP-AES) finish. The Au-AA25 fire assay method is an ore grade analysis using a 30g aliquot. The aliquot is mixed with flux composed of PbO and SiO2 with variable amounts of borax, soda ash and other reagents. The flux and sample are mixed, then heated at high temperature (>1,000°C) to decompose rock lattices and allow gold within the sample to be collected into a lead button. The button is placed in a porous cupel and heated again in an oxidizing environment to convert lead to lead oxide that is absorbed into the cupel, leaving the precious metals behind as a doré bead or prill. The gold content of the prill is then determined by atomic adsorption spectrometry.Both analyses are preceded by the preparation package Prep-31Y whereby the entire sample is crushed to 70% passing 2mm, a 250g split is collected by rotary splitter and pulverized to 85% passing 75 microns. Laboratory over-limits analysis methods were applied as required for both Sb and Au. A systematic QAQC protocol was employed that includes systematic insertion in the sample stream of certified reference materials and blank samples at a frequency of 1 in 10, plus analysis of duplicate pulp splits at a frequency of 1 in 30.About the Project and Historical ResourceDiscovered in the late 1970s, Trojárová was the focus of extensive surface and underground exploration over a 2km strike length from 1983 to 1995, with 63 core holes for a total of 14,330m, and 1.7km of underground workings completed. Efforts continued over the years as additional trenches were dug, and holes were drilled. Starting in 1990, underground development work began ultimately comprising a 300-meter-long adit connected to a 700-plus meter-long drive in the footwall of the mineralized zone with seven crosscuts into the mineralized zone for sampling purposes.These efforts culminated in a comprehensive study comprising drill logs, analyses, drill plans, maps and sections, deposit model studies, petrographic studies, metallurgical studies and more, now detailed in a multi-volume compendium of reports produced by the Slovak Geological Institute published in 1992, including a historical mineral resource estimate (see "Historical Resource Estimates" below). Per this historical estimate, at a cut-off grade of 1.0% antimony, Trojárová hosts 2.46 million tonnes averaging 2.47% antimony and 0.635 grams per tonne gold in a mineralized zone averaging 3.32 meters wide, containing approximately 60,000 tonnes of antimony in situ.Historical Resource EstimatesThe historical estimate related to the Trojárová Property was taken from a compendium produced by the Slovak Geological Survey, completed in March 1992 based on exploration work undertaking in the 1980s and 1990s. It is entitled (English translation): "FINAL JOB REPORT, PEZINOK-TROJAROVA, Geological Survey State Enterprise", report compendium number 78406 (Michel et al, 1992).The Slovak Geological Institute, the state agency that carried out all exploration and underground development work at Trojárová, classified the historical resources as "P1" and "C2" in the Slovak version of the Russian classification system, respectively. These are closest within the Canadian Institute of Mining, Metallurgy & Petroleum's ("CIM") classification system to "inferred mineral resources," which is defined by the CIM as that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence gathered through appropriate sampling techniques from locations such as outcrops, trenches, pits, workings and drill holes.The historical work carried out appears comprehensive, detailed and at a professional standard. The Company considers this historical data to be relevant as the Company will use these data as a guide to plan future exploration programs. The Company also considers the data to be reliable for these purposes. A qualified person has not done sufficient work to classify the historical estimate as current, and the Company is not treating the historical estimate as current.Qualified PersonThe technical contents of this release were reviewed and approved by David Murray, P.Geo, VP-Exploration for Military Metals and a qualified person as defined by National Instrument 43-101.For more information about Military Metals Corp. and its critical minerals initiatives, please visit: https://www.militarymetalscorp.com.LinkedIn: https://www.linkedin.com/company/military-metals/X: https://x.com/militarymetalsFacebook: https://www.facebook.com/profile.php?id=61564717587797About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.com or info@militarymetalscorp.comFor enquiries, please call 604-537-7556Forward-Looking StatementsThis news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes the timing of the mineral resource estimate being currently conducted, and its completion at all, future drilling and exploration work at Trojárová, the continuation of the value of antimony, and the future needs of Europe and the E.U. specifically. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include geopolitical developments related to the supply and value of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the property that is the subject of this news release, the results of any future exploration activities, which cannot be guaranteed, and any other future activities in respect of the property held by the Target. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282604 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Japantastics Launches Global Curator Platform Bringing Japan Craftsmanship to the World

jcn

TOKYO, February 3,2026 - (JCN Newswire via SeaPRwire.com) - Japantastics, Inc, a Tokyo-based company dedicated to promoting and distributing authentic Japan-made products to a global audience, has announced the official launch of Japantastics.jp, an online commerce platform that discovers and promotes unique, high-quality Japan-made products - focusing on craftsmanship, engineering, and stories that have long remained hidden beyond Japan's borders.Japan is home to a remarkable depth of artisanal skill and manufacturing excellence. Yet while global interest in Japan continues to rise — reflected in 40+ million visitors in 2025 — many highly skilled artisans and small manufacturers remain oriented entirely toward the domestic market. As a result, much of Japan’s finest craftsmanship remains difficult to encounter outside the country.Japantastics was founded to fill this divide, and curate products based on craft integrity, technical excellence, and cultural context, introducing makers whose work reflects years—often decades—of dedication and refinement. Rather than functioning as a conventional e-commerce marketplace, the Japantastics platform serves to discover and illuminate unique Japan-made crafts and products and will continue to broaden its lineup by discovering and introducing exceptional, lesser-known items from across the country.“Interest in premium Japanese products abroad continues to expand,” said Aki Tsukioka, Co-founder of Japantastics, Inc. "However, many artisans lack the resources, language support, and international channels needed to reach customers overseas. Japantastics exists to bridge that gap—not by simply selling products, but by communicating the value systems, techniques, and stories behind them."At the core of Japantastics is a belief that truly meaningful products are not disposable commodities, but lifelong tools shaped by human intention. By working closely with artisans and manufacturers, the company aims to present Japan-made goods not as trends, but as enduring objects that reward long-term use and appreciation. Each product is introduced with its background, production philosophy, and practical relevance for modern life.The Japantastics platform will continue to expand its lineup by discovering lesser-known makers across Japan - ranging from traditional crafts to contemporary manufacturing - while maintaining a highly selective, story-driven approach to curation. With this model, Japantastics positions itself as a cultural bridge: connecting Japanese creators with global audiences who value authenticity, quality, and depth over mass production.About JapantasticsJapantastics, Inc. is a Tokyo-based company dedicated to introducing authentic Japan-made products to global audiences. Through careful curation and storytelling, the company connects Japanese artisans and small manufacturers with customers worldwide who seek products defined by craftsmanship, longevity, and cultural meaning. Visit Japantastics.jp.Media Contact: Japantastics, Inc. Email: japantastics@gmail.com Website: https://japantastics.jp  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Kleiner Perkins的莉·玛丽·布拉斯韦尔从扑克游戏中学到了风险的教训：“如果胜算在你这边，就把筹码推到中间”

admin

(SeaPRwire) -   莉·玛丽·布拉斯韦尔（Leigh Marie Braswell）喜欢冒险类游戏，尤其是涉及数学的游戏。 布拉斯韦尔在阿拉巴马州乡村长大，直到在麻省理工学院（MIT）读本科时才接触到扑克。而直到她在著名量化交易公司Jane Street实习时，才彻底迷上了这款游戏。 “我们在纽约不出去聚会——而是待在室内玩扑克，”布拉斯韦尔说，“就这样，我通过每天和Jane Street的人对玩真正学会了扑克。” 布拉斯韦尔随即加入了MIT扑克俱乐部，在那里她与亚历山大·王（Alexandr Wang）重逢——两人最初是在她高中三年级的一场数学竞赛中相识的。后来，布拉斯韦尔成为了Scale AI的早期员工，当时她对风险投资一无所知。 “我当时几乎不知道VC（风险投资）这个概念是什么，”她回忆道，“亚历克斯告诉我‘哦，我们要签署A轮融资条款清单了’。然后我就去谷歌搜索：‘什么是A轮融资条款清单？’” 如今身为Kleiner Perkins合伙人的布拉斯韦尔，或许并非典型的风险投资人，但她的风投之路是循序渐进后突然加速的。2020年，也就是她在Scale的最后一年，她开始进行天使投资：她的第一笔投资是Ambience Healthcare，该公司现在估值达11亿美元。在Founders Fund工作了两年多后，布拉斯韦尔加入了Kleiner——这家传奇公司正处于由Mamoon Hamid和Ilya Fushman领导的转型期。我花了六个多月时间了解Kleiner的团队（包括布拉斯韦尔），以讲述这场转型的故事（详见）。而布拉斯韦尔多次被提及是一颗冉冉升起的新星，不仅在Kleiner，在整个风投行业都是如此。 为什么？原因很简单：布拉斯韦尔是2025年出现的一些最受关注的AI交易背后的关键投资人。在Kleiner，她投资了Windsurf（被Alphabet收购并吸纳团队）和Neon（被Databricks收购）；而她在Founders Fund时投资的Chronosphere最终也被某公司收购。（是的，2025年对布拉斯韦尔来说是重要的一年——如果宽泛计算的话，她在风投行业已经六年了，而这个行业通常需要十年才能有一两个真正的退出案例。） 不过，布拉斯韦尔——她目前在Kleiner的投资组合包括Nooks、Convoke、Reevo、Avoca和Forge——并不完全认为自己是AI投资人。 “我确实把自己描述为相对通才型的投资人，”她说，“不过……你肯定希望拥有不公平优势，或者真正融入某些人群和网络。而当你审视这些人脉网络时——尤其是在当下，并且有充分理由——理想情况下是在AI领域及其周边。” 布拉斯韦尔在Scale工作期间就开始和王（Wang）定期举办扑克之夜，现在仍在继续——随着时间推移，这已成为她投资策略的一部分。这是一种反复使用的方式：寻找交易、建立与创始人的关系，以及帮助投资组合公司招聘人才。但这也是一种思维方式。 因为归根结底，扑克是关于追踪概率并在信息不完整的情况下做出决策——这与早期投资非常相似。尽管有些事情你无法知晓，但你可以了解自己的胜算。 “扑克教会我的核心教训，”布拉斯韦尔说，“也是我作为风投人所感激的：如果胜算在你这边，就把筹码推到桌子中央。” 独家消息……TRM Labs是一家为政府机构和私营部门开发打击犯罪软件的区块链分析公司，该公司完成了7000万美元的C轮融资，估值达10亿美元。你可以点击此处了解详情。 Term Sheet播客…… Term Sheet播客本周回归，我们最新的嘉宾是Chemistry的Kristina Shen。2024年，Shen辞去了Andreessen Horowitz普通合伙人的职务，与Mark Goldberg和Ethan Kurzweil共同创办了新的风投公司Chemistry。Kristina和我聊了从零开始创办风投公司、她对AI收入的看法以及医疗健康领域的话题。 明天见， 艾莉·加芬克尔（Allie Garfinkle）X账号： 邮箱： 为Term Sheet newsletter提交交易信息。 乔伊·艾布拉姆斯（Joey Abrams）策划了今日通讯的交易板块。。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。